HAPILA becomes a teenager

Gera, Germany: – High-potency active ingredient specialist CDMO HAPILA GmbH (HAPILA) has entered its teenage years’ with the celebration of the 13^th anniversary of its founding in 2007.

HAPILA will mark the anniversary on May 25 with communications to all its partners and staff, whether or not they are working remotely because of the Covid-19 crisis.

Deepening contacts

HAPILA CEO Dr. Uwe Müller commented: “We would like to say thanks to all customers and supporters, who went with us on our way to become appreciated for our practical solutions for sophisticated drug substances.”

“The anniversary is an opportunity for us to renew contacts with our stakeholders in Big Pharma and in small and medium sized companies that are looking for a partner in synthesis and process development for API manufacturing,” he said.

HAPILA is also looking forward to networking with present and potential partners at two upcoming events,  Chemspec Europe opening November 11 in Cologne, and CPhI Worldwide opening on October 13 in Milan.

Working across the API value chain

“Since we were founded in 2007, HAPILA has become a highly experienced active ingredients -manufacturer involved in all parts of the API value chain from development of first synthetic routes to scale up to manufacturing sized batches including all necessary analytics and regulatory documentation,” said Dr. Müller

“As we move towards our twenties, we will continue to offer value and innovation in the synthesis  of small molecules, steroids and their impurities, industrial scale up and GMP manufacturing, analytics, long-term stability tests, high efficiency purification with our patented HAPIpur®-technology,” he concluded.

About HAPILA GmbH

HAPILA GmbH is a Contract developer and manufacturer (CDMO) that provides high-value services to pharma, biotech and fine chemicals client companies in the development and GMP manufacture of active pharmaceutical ingredients (APIs).

HAPILA is an independent company with particular experience in GMP-related development and GMP manufacturing, offering full regulated service for API (IMPD, ASMF) to very high scientific and quality assurance (QA) levels.

It supports the development and manufacture of drug products with patented processes and in-depth experience in the API value-creation chain from synthesis through purification to particle design.

The company’s mission is to supply exclusive products of highest quality, potency and safety in compliance with GMP and environmental protection guidelines. All HAPILA teamwork is focused on product quality and customer satisfaction.

All HAPILA chemical synthesis is carried out in-house at its GMP certified plants and laboratories at Gera, Thuringia, in east-central Germany.

When combined with purification and particle design, HAPILA’s chemical synthesis services cover the complete API value-creation chain, enabling it to be a highly efficient bridge-builder between API production and pharmaceutical end-use.

Further information at: https://www.hapila.de/en/home.html